Thus the ongoing preclinical and clinical trial phase I/II studies and future phase II studies investigating the role of ARDT1/2 specific inhibitors in ARTD9 or BCL2-positive and -negative DLBCL-NOS subtypes will certainly clarify whether the proposed functional crosstalk of ARTD1 and ARTD7-9 may also exist in DLBCL. The gene discussed is PARP9; the disease is diffuse large B-cell lymphoma.